NCT00525031 - Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Melanoma

Interventions

DRUG

Temozolomide (TMZ)

150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.

DRUG

Pegylated Interferon Alpha-2b (PGI)

0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston